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Update on transfusion solutions during surgery: 
review of hydroxyethyl starches 130/0.4
Objectives: Restoration of circulation is crucial in the surgical patient management. Colloids 
and crystalloids are widely used for blood volume therapy. We reviewed recent trials to evaluate 
efficacy and safety of hydroxyethyl starch (HES) 130/0.4 during surgery.
Material and methods: A subjective, not systematic, review of literature was performed. 
Papers were searched to answer questions about efficacy of HES, its impact on coagulation and 
inflammation and its effects on pulmonary mechanics and renal function.
Conclusions: HES 130/0.4 is effective for volume therapy and is less expensive than human 
albumin. Its effects on coagulation and renal function are manageable; it may ameliorate 
  pulmonary permeability and reduce inflammation.
Keywords: HES, colloids, volume loading, coagulation, inflammation, surgery, renal function, 
pulmonary mechanics
Hydroxyethyl starch (HES) solutions are synthetic colloids used to correct   hypovolemia. 
HES contains glycogen-like modified natural polysaccharides1,2 and can be classified 
according to their molecular weight (MW), concentration, and degree of substitution. 
Hydroxyethyl starch 130/0.4 (mean molecular weight, 130 kd; degree of substitution, 
0.4) is a relatively new medium-molecular-weight HES solution. The development of 
newer starch-based plasma volume expanders has been driven by the need to improve 
safety and pharmacological properties while maintaining the volume efficacy of 
  previous HES generations. Reductions in MW and molar substitution (MS) have led 
to products with shorter half-lives, improved pharmacokinetic and pharmacodynamic 
properties, and fewer side effects.3 Earlier products were all derived from amylopectin 
extracted from waxy maize starch but it is inaccurate to refer to HES as if they were 
only one homogenous product because modifications to MW and the degree and   pattern 
of substitution result in distinct and observable differences between and within the 
different generations of HES.
The same is true for starches of similar structure that have been derived from 
  different source materials: waxy maize and potato. Two third-generation starches 
based on these two materials are currently available in various formulations.   According 
to the results of one study, potato and waxy maize-derived HES solutions are not 
bioequivalent.4 Therefore, findings obtained from studies using one type may not be 
valid for the other.
Early experimental studies produced reports of increased mortality rates in 
mice that received HES solutions before an endotoxin challenge and in a rat 
  endotoxin model, HES 10% (200/0.5) was less effective than albumin in preventing 
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  lipopoly  saccharide-induced myocardial dysfunction5. There 
is continuing concern regarding possible adverse effects of 
HES solutions including coagulopathy, anaphylactoid reac-
tions, and renal impairment.
It has been suggested that the modern generation HES 
solutions, 6% HES (130/0.4), may be less likely to induce 
nephrotoxicity and may impair blood coagulation less than 
other HES solutions and thus, may be used in larger doses 
without increasing the risk of postoperative bleeding.
In this paper we review some of the relevant articles 
regarding the use of HES 130/0.4 during surgery, looking for 
answers to five of the most asked questions on this subject.
Is HES 130/0.4 more efficient  
in plasma substitution than  
other colloids?
A recent systematic review of randomized clinical   studies 
on the use of fluid therapy in various types of surgical 
  procedures found no evidence to recommend one type of 
fluid therapy over another. There was not sufficient evidence 
to provide guidance on the optimal amount of fluid to use 
in elective surgical procedures.6 It was therefore concluded 
that guidelines for perioperative fluid management must 
be procedure-specific; in the absence of firm evidence for 
one approach or another, individualized, goal-directed fluid 
administration should be used. Currently, it appears that a 
restrictive rather than a liberal fluid regimen is beneficial in 
patients undergoing colorectal surgery. Conversely, patients 
suffering from systemic inflammation appear to benefit from 
aggressive fluid replacement, as demonstrated by Rivers 
et al.7 This is in line with the conclusion of   Brandstrup, 
who critically evaluated the evidence behind current 
  standard fluid therapy and the effect of fluid therapy on the 
  outcomes of surgery.8 The latter author reported that choice 
of   standard fluid therapy is not generally evidence-based and 
that   methodological flaws during attempts to restrict fluid 
therapy actually result not in restriction but simply replace-
ment of lost fluids. Therefore, it is recommended to replace 
lost fluid and avoid fluid overload, which echoes earlier 
  recommendations to adopt goal-directed   intraoperative 
fluid therapy.9
Despite the absence of clear recommendations for any 
particular fluid therapy, there is plentiful debate about the 
relative merits of crystalloid or colloid, and even about 
  different types of colloids. As recently remarked by Boldt in 
an editorial, “Researchers who show crystalloid to be superior 
always find crystalloid superior, whereas colloid supporters 
always favor colloids”.10
Adequate restoration of intravascular volume remains 
the crucial therapeutic maneuver in managing the   surgical 
patient. It is generally believed that three to four times 
more crystalloid than colloid volume is needed to achieve 
an equivalent plasma volume expansion. However, in the 
SAFE trial,11 in which fluid administration was blinded, the 
ratio of albumin to saline was 1:1.4 and thus much less than 
expected. While the choice between colloid and crystalloid 
solutions continues to generate controversy, the dispute 
has been enlarged to a colloid/colloid debate (eg, dextrans, 
gelatins, HES solutions).
Vanhoonacker et al12 studied 157 electively scheduled 
patients randomly allocated to 6% HES (n = 85) or gelatine 
(n = 72) CPB (cardiopulmonary bypass) priming. According 
to their data, HES 130/0.4 is a safe alternative to gelatine 
pump prime with a volume effect persisting longer in the 
postoperative phase, mandating less volume expansion with 
artificial colloid during the first 24 postoperative hours. 
  Albumin supplements occurred more frequently in the HES 
group between 2 and 3 hours postoperatively but total artifi-
cial colloid supplement was significantly higher in the gelatin 
group (13.36 versus 8.96 mL/kg, P , 0.001). There were no 
differences in the number of packed red cells, fresh frozen 
plasma, or platelets transfused between the two groups.
Hanart et al13 compared 4% albumin with 6% HES 
130/0.4 in 190 children undergoing cardiac surgery, ran-
domized to receive either 4% albumin (n = 59) or 6% HES 
130/0.4 (n = 60) for intraoperative fluid volume replacement 
including the cardiopulmonary bypass priming fluid. Volume 
of colloid used intraoperatively was similar in both groups.
They concluded that in children undergoing cardiac sur-
gery, 6% HES 130/0.4 may represent an alternative to 4% 
albumin for intraoperative fluid volume replacement because 
of its lower cost.
Is blood loss and risk of bleeding 
increased with HES 130/0.4 during 
surgery?
The in vitro and in vivo effects of various HES products on 
coagulation and platelet function have been investigated in a 
number of studies. Overall, the more rapidly degradable HES 
products have been found to have a greatly reduced effect on 
the coagulation process compared to older products.14,15
HES macromolecules interact with platelets and the 
coagulation cascade, causing a decrease in factors such as 
Factor VIII and von Willebrand factor but the exact mecha-
nisms have still not been fully elucidated.16 There have been 
consistent reports of coagulation impairment since slowly International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
289
Hydroxyethyl starches
degradable HES preparations were introduced into   clinical 
practice. These HES preparations decreased circulating 
plasma concentrations of coagulation factors in volunteers 
and patients, even when used below the recommended 
maximum doses.15,17–22
It is recommended that the maximum doses of HES not 
exceed 20 and 33 mL/kg per day for high- and medium-
molecular-weight HES solutions, respectively.
Treib et al carried out systematic studies of the effects 
of a range of HES preparations and found that the   products 
with higher MS had a profound effect on coagulation 
and platelet function but suggested that newer HES 
  preparations should only have minimal effects.23,24 Results 
of in vitro   studies of the coagulation process indicate that 
the altered   pharmacokinetics of the newer generation of HES 
  preparations have led to products with moderate effects on 
coagulation and platelet function.18,25–27 However, in vitro 
studies have limitations and may be misleading since, in 
the absence of the normal compensatory mechanisms, at 
least part of the observed effects may be attributable to 
simple hemodilution or to the presence of calcium in the 
solvents.28,29 The biochemical mechanisms causing dilutional 
coagulopathy following infusion of hydroxyethyl starch 
130/0.4 have been recently studied by Fenger-Eriksen et al30 
acquired fibrinogen   deficiency constitutes the most important 
determinant of the coagulopathy.
A total of 20 bleeding patients were examined;30 blood 
loss was substituted with HES up to a target level of 30% 
and thromboelastometry, platelet count, thrombin genera-
tion, and the activities of von Willebrand factor, coagulation 
  factor II, FVII, FVIII, FIX, FX, and FXIII were measured. All 
coagulation factor activities were reduced. Ex vivo addition 
of fibrinogen corrected the coagulopathy completely.
The most useful evidence concerning the safety of waxy 
maize-derived 6% HES 130/0.4 is derived from extensive 
clinical studies in many types of major surgery. Although 
very high doses have been used,31 no adverse effects on 
coagulation have been reported compared to controls using 
lower doses.
In one high-dose study, Ellger et al32 found that 6% HES 
130/0.4, when given in doses up to 50 mL/kg, had similar 
effects on coagulation as 30 mL/kg HES 200/0.5 plus   gelatin. 
In this study, 40 patients undergoing elective surgery for 
urology-related cancer were randomized to receive one of the 
HES preparations. Coagulation parameters were measured at 
five time points during and after surgery. The authors noted 
that there was some deterioration of   coagulation   during 
surgery but that this was most likely the result of blood loss 
and hemodilution. No significant differences were found 
between groups in terms of hemoglobin, hematocrit, plate-
let count, coagulation factors (prothrombin time, partial 
thromboplastin time, von Willebrand factor, Factor VIIIc), 
or blood loss. Similar results were obtained in a study of 120 
patients undergoing elective coronary artery bypass surgery.33 
Patients were randomized to volume replacement either with 
6% HES 130/0.4 (up to 50 mL/kg) or 6% HES 200/0.5 (up 
to 33 mL/kg) with volume requirements in excess of these 
doses being met with gelatin. Despite being used at a median 
dose of 49 mL/kg, HES 130/0.4 did not increase blood loss 
and transfusion requirements compared to the lower dose of 
HES 200/0.5. The authors also noted that patients random-
ized to be treated with pentastarch received three times as 
much gelatin as those in the tetrastarch group and speculated 
that this should, if anything, have biased this group towards 
reduced blood loss.
Safety of HES 130/0.4 in patients 
with renal dysfunction: comparison 
with other colloids
Concerns about the possible deleterious effects of HES 
on renal function were first raised by Legendre et al in a 
  retrospective study investigating the association between HES 
exposure of organ donors and the subsequent tissue storage 
in the recipients.34 Cittanova et al35 later found a link between 
the use of HES 200/0.62 in kidney donors and the subsequent 
need for hemodialysis in the recipients, but Deman et al could 
not confirm these results in their retrospective analysis.36 
The authors suggested that the nephrotoxicity noted by Leg-
endre et al34 might have resulted from the use of a particular 
preservation agent. Other researchers also failed to find any 
deterioration in renal function associated with the use of vari-
ous HES preparations: 6% HES 200/0.5 and HES 70/0.5,37 
6% HES 200/0.5, 6% HES 200/0.62, and 6% HES 450/0.7,38 
even when high doses were used.31 In a randomized study of 
elderly patients undergoing cardiopulmonary bypass surgery, 
Boldt et al found no difference in the levels of kidney-specific 
proteins between patients who received 6% HES 130/0.4 and 
those who received gelatin.39 In another randomized study 
with similar patients, comparing the same HES agent with 
5% albumin, Boldt et al again found no   difference in renal 
function between the two groups.40 In the considerable body 
of clinical data on the third-generation HES 130/0.4, there 
have been no reports of adverse effects on renal function 
over and above those seen in control groups, in patients who 
are considered to be at particular risk, such as those with 
previous mild to severe renal dysfunction,41–43 the elderly,44 International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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and those receiving   high-dose therapy.31   Fenger-Eriksen et al44 
performed studies in the area and found that a colloid-based 
fluid regime (6% HES 130/0.4) may preserve renal function 
to a greater extent than   crystalloids in patients undergoing 
spinal surgery. Similarly, Godet et al45 suggested that 6% 
HES 130/0.4 was as safe as gelatin   (Plasmion®; Fresenius 
France Pharma, Sevres, France) in patients with prior renal 
dysfunction undergoing abdominal aortic surgery. Although 
baseline renal function was impaired in all patients (creati-
nine clearance [CrCl] less than 80 mL/min), no drug-related 
unfavorable effects on renal function were found using HES 
130/0.4 compared to gelatin.
One of the criticisms directed against many earlier   studies, 
is that the follow-up periods have been relatively short.43 Fifty 
patients undergoing cardiac surgery were   randomized to 
either 6% HES 130/0.4 or 5% human   albumin given peri-
operatively until the second   postoperative day. At a 60-day 
follow up, it was found that kidney   function in patients receiv-
ing tetrastarch was as preserved as with albumin. Although 
concentrations of kidney-specific   proteins increased after 
surgery in both groups, there was no   difference between 
groups. None of the patients developed acute renal failure 
leading to renal replacement therapy, either during hospital 
stay or in the follow-up period.
Three recently published studies confirm these findings. 
In a randomized study of 50 patients assigned to either 
a   balanced regimen (6% HES 130/0.42 plus crystalloid 
  solution) or a saline-based regimen (saline plus MS of the 
HES) kidney integrity was less altered with the HES 130/0.42. 
Levels of glutathione transferase alpha and   neutrophil gelati-
nase-associated lipocalin were raised in both groups, but less 
so in the group with the plasma-adapted solutions.46
Another recent publication contains preliminary results 
of an observational study of pediatric patients aged up to 
12 years undergoing various types of surgery while receiving 
6% HES 130/0.42. This noncomparative study evaluated the 
perioperative use of HES 130/0.42 in 1,000 children, with 
a particular focus on cardiovascular stability, hemodilution, 
acid-base balance, renal function, blood coagulation, and 
hypersensitivity. Reports on the first 300 children have shown 
no serious effects on renal function.47
It has been suggested from perioperative studies in 
  low-risk patients who received cumulative doses in the range 
of only 50 mL/kg body weight, that HES 130/0.4 may be less 
likely to induce nephrotoxicity than HES 10%.
In surgical ICU patients, the incidence of ARF was   similar 
in patients who received predominantly HES 130/0.4 fluid 
therapy and in those who received predominantly gelatin 
4%.48,49 In summary, the published data on this topic   suggest 
that there are differences between the older and newer genera-
tions of HES and that the reports of adverse effects on renal 
function should not be extrapolated to newer HES products. 
Moreover the Cochrane Collaboration Review [Dart AB, 
Mutter TC, Ruth CA, Taback SP, Hydroxyethyl Starch (HES) 
versus other fluid therapies: effects on kidney function. Data-
base of Systematic Reviews 2010, Issue 1] concluded that 
“there is inadequate clinical data to address the claim that 
safety differences exist between different HES products”.
Pulmonary mechanics: comparison 
of HES 130/0.4 and other fluids
Crystalloids may promote fluid extravasation in the lungs 
and formation of pulmonary edema since they tend to lower 
colloid osmotic pressure (COP). In contrast, colloids may 
decrease pulmonary fluid extravasation and the formation of 
pulmonary edema because of their capacity to increase COP. 
The so-called colloid-crystalloid controversy includes the 
relative propensity of fluid types to evoke pulmonary edema, 
which is not yet settled in the absence of direct   permeability 
and edema measurements in most studies.50 Indeed, the 
controversy is complicated by the fact that the potentially 
protective role of COP may diminish when   permeability 
is increased, while the propensity for edema formation 
may increase, unless hydrostatic pressure is kept low, as 
  demonstrated in experimental and human studies.51–53
Cardiac and major vascular surgery are often   complicated 
by hypovolemic hypotension, necessitating fluid therapy, but 
the optimal type of fluid for this purpose is hotly debated.50,54–61 
Cardiac and major vascular surgery,   involving ischemia and 
reperfusion, are well known risk factors for a systemic inflam-
matory response and for acute lung injury/acute respiratory 
distress syndrome (ALI/ARDS),   associated with increased 
capillary permeability in the lungs in some patients, as 
measured by a noninvasive double radionuclide technique to 
detect pulmonary Ga-transferrin extravasation.62–66 This could 
thus affect the contribution of infusion fluids to pulmonary 
edema formation. Indeed, researchers have documented an 
increase in extravascular lung water (EVLW) after cardiac or 
major vascular surgery and fluid loading, at least transiently 
in some patients.57–59,67–70 Verheij et al71 hypothesized that 
colloid fluid loading would aggravate less edema formation 
in the lungs than saline   loading in the treatment of presumed 
hypovolemia after major surgery, even if complicated by 
increased pulmonary permeability. They also hypothesized International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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that hydroxyethyl starch (HES) or albumin loading would 
attenuate pulmonary edema attributable to increased perme-
ability as compared with gelatin loading. They therefore com-
pared filling pressure-guided fluid challenges72 with saline 
and with the colloids gelatin, HES, and albumin on their 
effects on pulmonary capillary permeability, EVLW, COP, 
and the lung injury score (LIS) in 67 presumably hypovolemic 
patients after cardiac or major vascular surgery. In this study 
more saline was infused than colloid solutions (P , 0.005). 
The COP increased in the colloid groups and decreased in 
patients receiving saline. Cardiac output increased more in 
the colloid groups. At baseline, pulmonary leak index (PLI) 
and EVLW were above normal in 60% and 30% of the 
patients, with no changes after fluid loading, except for a 
greater PLI decrease in HES than in gelatin-loaded patients. 
The oxygenation ratio was improved in all groups. In the 
colloid groups, the LIS was increased because of a decrease 
in total respiratory compliance, probably associated with an 
increase in intrathoracic plasma volume. It was concluded 
that saline or colloids do not affect permeability edema in 
ALI after cardiac or major vascular surgery, provided that 
fluid overloading is avoided, and except for HES which may 
ameliorate increased permeability. The LIS, however, may 
slightly increase after colloid versus saline loading, because 
of greater intrathoracic plasma volume expansion decreasing 
total respiratory compliance, thus indicating that changes in 
LIS (and respiratory compliance) during fluid loading do not 
represent only changes in permeability edema.
Does HES 130/0.4 reduce 
inflammatory response to surgery?
As with all forms of trauma, surgery triggers a systemic 
inflammatory response with the release of inflammatory 
mediators into the systemic circulation. Proinflammatory 
cytokines, such as interleukin-6 (IL-6) and IL-8, play an 
important role in regulating the acute inflammatory phase. 
Cell adhesion molecules, such as E-selectin, endothelial 
leukocyte adhesion molecule-1 (ELAM-1), and intercellular 
adhesion molecule-1 (ICAM-1) regulate the interaction away 
immune cells with the endothelium and the extracellular 
matrix. It has been demonstrated that release of IL-6 
correlates with the severity of surgery.72 In particular, surgery 
of the intestine is associated with a greater inflammatory 
response than other types of surgery,73 and the elderly popula-
tion may also show an enhanced inflammatory response.74,75 
It is, therefore, of interest to assess the effects of volume 
replacement solutions on the mediators of inflammation.
In a study of patients undergoing abdominal surgery, Lang 
et al76 found a significantly lower increase of the proinflam-
matory cytokines IL-6 and IL-8 in patients receiving 6% HES 
130/0.4 compared to those receiving lactated Ringer’s solu-
tion. There were also significantly lower serum concentrations 
of soluble ICAM-1 (sICAM-1) in the HES group.
Likewise, in patients undergoing major abdominal sur-
gery, Boldt et al77 reported a similar attenuation of plasma 
levels of IL-6 in patients receiving 6% HES 130/0.4 compared 
to those receiving 5% albumin. Plasma levels of endothe-
lial adhesion molecules (sELAM-1, sICAM-1) were also 
significantly lower in the HES group, returning to normal 
on the day after surgery and remaining elevated in patients 
receiving albumin. In a study of elderly patients undergoing 
cardiac surgery, inflammatory response was similar in groups 
receiving 5% albumin and those receiving 6% HES 130/0.4, 
whereas endothelial activation was lower in the HES group.40 
Boldt speculates that the beneficial effect of HES 130/0.4 on 
inflammation and endothelial activation may be the result 
of some direct, substance-specific effects on endothelial 
cells resulting in reduced release of adhesion molecules.77 
Using endothelial cell cultures, Collis et al78 found that 
lipopolysaccharide-stimulated expression of adhesion ligand 
P-selectin was inhibited by HES.
Volta et al79 reported that HES 130/0.4 was able to 
selectively inhibit the activity of matrix metalloproteinase-9 
(MMP-9) in vitro compared to lactated Ringer’s solution. 
This was confirmed in 36 patients scheduled for colon cancer 
surgery who were randomized to 6% HES 130/0.4, 3.4% 
polygeline or lactated Ringer’s solution. After surgery, plasma 
levels of MMP-9 and tissue inhibitor of MMP-9 (TIMP-9) 
were higher in all three groups, but they were significantly 
lower in the tetrastarch group than in the other two groups.
In a number of in vitro and animal studies light has been 
shed on the possible mechanisms by which HES might affect 
the inflammatory process. Using cultured human microvascular 
endothelial cells and mice, Dieterich et al80 found that physi-
ologically relevant concentrations of tetrastarch were able to 
reduce neutrophil adhesion in vitro, while vascular leakage 
and pulmonary edema induced by hypoxia exposure were 
reduced in animals treated with HES. Nohé et al81 studied 
the expression of adhesion molecules on native and cytokine-
activated endothelium from umbilical veins after pretreatment 
with gelatin and various preparations of dextran and HES. The 
authors concluded that synthetic colloids inhibit neutrophil 
adhesion by a neutrophil-dependent mechanism rather than 
interfering with endothelial cell activation.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Conclusion
The evidence base for HES 130/0.4 is strong; overall, 
there are more than 50 published studies reporting on the 
  coagulation effects of waxy maize-derived HES 130/0.4, 
including more than 20 Phase II to IV studies. These studies 
confirm that, unlike earlier generation HES preparations, the 
tetrastarches have minimal effects on coagulation.
Results of nine clinical trials on renal function support 
the safety of HES 130/0.4, and two recently published trials 
confirm that potato-derived HES 130/0.42 has no adverse 
effects on renal function, but there are inadequate clinical 
data to address the claim that safety differences exist between 
  different HES products. Intravascular volume replacement 
with HES 130/0.4 may reduce the inflammatory response in 
patients undergoing major surgery compared to a crystalloid-
based   volume therapy. Finally, the type of fluid used for volume 
loading does not affect pulmonary permeability and edema, 
and HES may ameliorate increased permeability (Figure 1).
Intravascular volume replacement with HES
130/0.4 may reduce the inflammatory response in
patients undergoing major surgery
The tetrastarches have minimal effect on
coagulation.
The type of fluid used for volume
loading does not affect pulmonary
permeability and edema, and
HES might ameliorate increased
permeability.
HES 130/0.4 is effective for
volume therapy and is less
expensive than human albumin Nine clinical trials on renal function
demonstrate the safety HES 10/0.4 and
two recently published trials confirm that
potato-derived HES 130/0.42 has no
adverse effects on renal function
5
2
4
1
3
Figure 1 Results for each of the five questions investigated in the present study.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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